Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SRTA
SRTA logo

SRTA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.240
Open
5.200
VWAP
5.14
Vol
883.77K
Mkt Cap
453.40M
Low
5.030
Amount
4.55M
EV/EBITDA(TTM)
--
Total Shares
86.53M
EV
411.92M
EV/OCF(TTM)
--
P/S(TTM)
2.01
Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. Its other clinical services include cardiac care and others.
Show More

Events Timeline

(ET)
2026-05-06
07:40:00
Strata Adjusts FY26 EBITDA Guidance to $29M-$33M
select
2026-05-06
07:40:00
Company Reports Q1 Revenue of $67.38M, Exceeding Expectations
select
2026-03-03 (ET)
2026-03-03
07:10:00
Will Heyburn: Company Aims for 30% Annual EBITDA Growth
select

News

Newsfilter
8.5
06-24Newsfilter
Strata Completes $21.5 Million Acquisition of HLT-NRP
  • Acquisition Completed: Strata has successfully acquired Heart and Lung Transplant National Recovery Program (HLT-NRP) for $21.5 million, executed at a mid-single-digit multiple of Adjusted EBITDA, aligning with Strata's capital deployment strategy and expected to significantly enhance its transplant clinical business scale and market share.
  • Growth Potential: This acquisition will substantially expand Strata's network of transplant surgeons, particularly in key markets like Florida and California, thereby improving the company's responsiveness and service quality in transplant services, which is likely to enhance customer satisfaction and competitive positioning.
  • Financial Performance Outlook: HLT-NRP is projected to generate approximately $10 million in revenue and $3.1 million in Adjusted EBITDA for 2026, further driving Strata's overall financial performance and supporting the company's long-term profitability goals.
  • Strategic Integration Benefits: By integrating HLT-NRP, Strata can efficiently leverage its experienced transplant recovery surgeons while maintaining high clinical service standards, which is expected to provide robust support for the company's future growth and market expansion.
Newsfilter
8.5
05-07Newsfilter
Strata Critical Medical Announces Expiration of Warrants
  • Warrants Expiration: Strata Critical Medical announced that its Public Warrants (NASDAQ:SRTAW) and Private Placement Warrants expired at 5:00 p.m. ET on May 7, 2026, marking the end of this financing tool and potentially impacting future capital structure.
  • Healthcare Service Network: Strata operates one of the largest air transport and surgical services networks in the U.S. healthcare industry, focusing on transplant hospitals and organ procurement organizations, which enhances the efficiency of organ recovery processes.
  • Core Service Integration: The company's core services include air and ground logistics, surgical organ recovery, organ placement, and perfusion staffing and equipment solutions for cardiovascular surgery centers, showcasing its comprehensive capabilities in the medical services sector.
  • Brand Strategy: Strata strengthens its market position in the transplant industry through its Trinity Medical Solutions and Keystone Perfusion brands, aiming to enhance customer satisfaction and competitive edge by integrating resources.
seekingalpha
9.5
05-06seekingalpha
Strata Critical Medical Reports Strong Q1 2026 Earnings with 87% Revenue Growth
  • Significant Revenue Growth: Strata Critical Medical reported an impressive 87.4% year-over-year revenue increase in Q1 2026, reaching $67.4 million, with Logistics revenue rising 32.4% to $47.6 million, demonstrating the company's strong market performance and business expansion capabilities.
  • Cash Flow Improvement: The company generated $3.9 million in operating cash flow and $2.1 million in free cash flow this quarter, marking a significant enhancement in cash generation capacity before aircraft acquisitions, with expectations for further improvements in earnings quality and cash conversion in upcoming quarters.
  • Acquisition Strategy Advancement: The announcement of the $1 million acquisition of Ohio Valley Perfusion Associates is expected to contribute approximately $100,000 of adjusted EBITDA for the remainder of the year, showcasing the company's proactive approach to M&A and financial flexibility.
  • Stable Outlook: Management reiterated its 2026 revenue guidance of $260 million to $275 million and adjusted EBITDA of $29 million to $33 million, maintaining confidence in future performance despite challenges from fuel price volatility and market demand fluctuations.
seekingalpha
9.5
05-06seekingalpha
Blade Air Mobility Q1 Earnings Exceed Expectations
  • Earnings Beat: Blade Air Mobility reported a Q1 GAAP EPS of $0.03, exceeding expectations by $0.07, which indicates a significant improvement in profitability and boosts investor confidence.
  • Strong Revenue Growth: Q1 revenue reached $67.4 million, a 24.1% year-over-year increase, surpassing market expectations by $3.73 million, reflecting the company's competitive edge and growth potential in the market.
  • Logistics Performance: Logistics revenue and gross profit grew by 32.4% and 29.9% year-over-year, respectively, showcasing Strata's robust organic growth and solidifying its market position in medical logistics.
  • Adjusted EBITDA Growth: Q1 adjusted EBITDA was $6.4 million with a net income of $2.4 million, indicating profitability in ongoing operations and strengthening the financial foundation for future expansion.
seekingalpha
9.5
05-05seekingalpha
Blade Air Mobility to Announce Q1 Earnings on May 6
  • Earnings Announcement: Blade Air Mobility (SRTA) is set to announce its Q1 2023 earnings on May 6 before market open, with a consensus EPS estimate of -$0.04, indicating ongoing challenges in profitability.
  • Revenue Growth Expectations: Analysts project Blade Air Mobility's revenue to reach $63.67 million, reflecting a 17.3% year-over-year increase, suggesting potential sales growth in the market despite the anticipated losses.
  • Strategic Expansion: Strata Critical Medical (SRTA) has raised its 2026 revenue guidance to between $260 million and $275 million, driven by 35% organic growth, showcasing the success of its acquisition strategy and strong market demand.
  • Stock Price Reaction: Strata Critical Medical's stock surged by 21% following its Q4 earnings report, indicating investor optimism regarding its revenue growth and future prospects.
Newsfilter
1.0
04-09Newsfilter
Strata Critical Medical to Present at Needham Conference
  • Conference Announcement: Strata Critical Medical will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 1:30 PM ET, showcasing its latest advancements in medical logistics, which is expected to attract investor and industry attention.
  • Webcast Availability: The event will feature a webcast accessible through the company's investor relations section, ensuring transparency and enhancing engagement with investors, thereby improving the company's public image.
  • Business Expansion: Strata Critical Medical is strategically expanding its service portfolio through acquisitions and organic growth, particularly highlighting its subsidiary Trinity Medical Solutions' leadership in organ transportation, demonstrating the company's strong competitive position in the healthcare services market.
  • Forward-Looking Statements: The press release includes forward-looking statements that emphasize future growth opportunities and potential risks, indicating management's confidence in the company's future while also cautioning investors to consider external factors that may impact performance.
Wall Street analysts forecast SRTA stock price to rise
2 Analyst Rating
Wall Street analysts forecast SRTA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
8.00
Averages
9.63
High
11.25
Current: 0.000
sliders
Low
8.00
Averages
9.63
High
11.25
Ladenburg
Jon Hickman
Buy
maintain
AI Analysis
2026-05-07
Reason
Ladenburg
Jon Hickman
Price Target
AI Analysis
2026-05-07
maintain
Buy
Reason
Ladenburg analyst Jon Hickman raised the firm's price target on Strata Critical Medical to $11.50 from $11.25 and keeps a Buy rating on the shares.
Craig-Hallum
Bill Bonello
initiated
$8
2026-03-25
Reason
Craig-Hallum
Bill Bonello
Price Target
$8
2026-03-25
initiated
Reason
As previously reported, Craig-Hallum analyst Bill Bonello initiated coverage of Strata Critical Medical with a Buy rating and $8 price target. Over the past year, the company has executed a major strategic transformation and, as a result, it is not well-covered and its growth prospects are underappreciated, the firm argued. Craig-Hallum expects multiple expansion as the market starts to understand the business, becomes more confident in the growth prospects, and comes to believe that estimates are conservative.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SRTA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Strata Critical Medical Inc (SRTA.O) is 138.89, compared to its 5-year average forward P/E of 40.34. For a more detailed relative valuation and DCF analysis to assess Strata Critical Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
40.34
Current PE
138.89
Overvalued PE
117.98
Undervalued PE
-37.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
99.36
Current EV/EBITDA
597.99
Overvalued EV/EBITDA
328.14
Undervalued EV/EBITDA
-129.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.40
Current PS
1.55
Overvalued PS
1.65
Undervalued PS
1.14

Financials

AI Analysis
Annual
Quarterly

Whales Holding SRTA

T
Third Point LLC
Holding
SRTA
+1.22%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Strata Critical Medical Inc (SRTA) stock price today?

The current price of SRTA is 5.16 USD — it has decreased -1.53

What is Strata Critical Medical Inc (SRTA)'s business?

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. Its other clinical services include cardiac care and others.

What is the price predicton of SRTA Stock?

Wall Street analysts forecast SRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTA is9.63 USD with a low forecast of 8.00 USD and a high forecast of 11.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Strata Critical Medical Inc (SRTA)'s revenue for the last quarter?

Strata Critical Medical Inc revenue for the last quarter amounts to 67.38M USD, increased 87.45

What is Strata Critical Medical Inc (SRTA)'s earnings per share (EPS) for the last quarter?

Strata Critical Medical Inc. EPS for the last quarter amounts to 0.02 USD, decreased -150.00

How many employees does Strata Critical Medical Inc (SRTA). have?

Strata Critical Medical Inc (SRTA) has 601 emplpoyees as of July 08 2026.

What is Strata Critical Medical Inc (SRTA) market cap?

Today SRTA has the market capitalization of 453.40M USD.